Drug and Pharmacology Database
ID: HT001125RFI0225Type: Sources Sought
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYFALLS CHURCH, VA, 22042, USA

Original Source

https://sam.gov/opp/4886e1f728c747c4a88377fa984808d2/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency (DHA), is seeking market research input for a Comprehensive Clinical and Dental Drug and Pharmacology Database. This database is crucial for the Department of Defense Medicine and Military Health System, serving as a primary source of drug information for clinical and dental applications. The RFI (HT001125RFI0225) aims to assess the capabilities of potential service providers, including their organizational structure and project management skills, with a focus on enhancing healthcare delivery within military frameworks. Interested organizations must submit their capability statements and contact information by 12:00 PM on March 25, 2025, and inquiries should be directed to Jeanna Butler or Theophilus Agyare via their provided emails.

    Point(s) of Contact
    Jeanna Butler
    jeanna.m.butler.civ@health.mil
    Theophilus Agyare
    theophilus.o.agyare.civ@health.mil
    Files
    Title
    Posted
    HT0011-25-RFI-0225 Drug and Pharmacology Database.pdf
    The Defense Health Agency (DHA) is seeking market research input for a Comprehensive Clinical and Dental Drug and Pharmacology Database. This resource is essential for the Department of Defense Medicine and Military Health System, serving as a primary source of drug information for clinical and dental usage. The RFI (HT001125RFI0225) aims to assess potential service providers' capabilities, including their organizational structure, financial resources, and project management skills. Responses will help determine the acquisition method, which may favor small businesses or open competition. Interested organizations must provide contact information, capability statements, and details if subcontracting is anticipated. The submission deadline is 12:00 PM, March 25, 2025, and inquiries should be directed to the specified Contracting Officer and Contract Specialist. The RFI does not constitute a request for proposals, and the government will not provide feedback on submissions. This initiative underscores the DHA's commitment to enhancing healthcare delivery within military frameworks by securing a robust database for medical and dental practitioners.
    Lifecycle
    Title
    Type
    Drug and Pharmacology Database
    Currently viewing
    Sources Sought
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary under the TRICARE pharmacy benefit. This procurement aims to evaluate the clinical and cost-effectiveness of medications, allowing manufacturers to submit quotes for both the Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). The selected pharmaceutical agents will be utilized in Military Treatment Facilities (MTFs) and the TRICARE retail network, emphasizing the importance of providing effective healthcare solutions while managing costs. Interested manufacturers must submit their quotes by March 20, 2025, and can direct inquiries to Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil or Tracy Banks at tracy.e.banks2.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotations for a Blanket Purchase Agreement (BPA) related to the Pharmacy Uniform Formulary and the Uniform Formulary Additional Discount Program. This procurement aims to secure pharmaceutical agents for inclusion in the DoD's integrated pharmacy benefits program, focusing on enhancing medication management for service members while ensuring cost-effectiveness and compliance with established pricing protocols. The initiative is particularly significant for managing high-value medications, such as those used in breast cancer treatment, and emphasizes the importance of accurate data representation and adherence to procedural changes within the Military Health System. Interested vendors must submit their quotes by March 20, 2025, and can direct inquiries to Tracy Banks at tracy.e.banks2.civ@health.mil or Julianne Canaley at julianne.m.canaley.ctr@health.mil.
    Systems, Engineering, and Integration Support
    Buyer not available
    The Defense Health Agency (DHA) is seeking information regarding Systems Engineering and Integration (SE&I) Support Services through a Request for Information (RFI) identified as HT0011-25-RFI-0226. The primary objective of this procurement is to identify potential contractors capable of enhancing DHA's IT systems, particularly focusing on the Electronic Health Record (EHR) for military health services, while ensuring compliance with cybersecurity requirements and supporting strategic IT initiatives. This opportunity is crucial for modernizing and maintaining military health IT systems, with the contract expected to span a 12-month base period and potentially include additional optional periods. Interested vendors must submit their responses by April 7, 2025, and can direct inquiries to Saera Khan at saera.khan.civ@health.mil or Marcus Riley at marcus.j.riley3.civ@health.mil.
    Health Technology Capability Statement Collection
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking insights from contractors regarding their capabilities in the Defense Health Information Technology sector as part of a Health Technology Capability Statement Collection initiative. This Request for Information (RFI) aims to enhance procurement decisions for fiscal year 2025 by evaluating vendors' abilities to adapt to emerging technologies, particularly in artificial intelligence (AI). The information gathered will contribute to a market research repository that supports the government's commitment to innovation in healthcare technology and procurement processes. Interested contractors must submit their capability statements electronically in PDF format by December 31, 2024, with responses accepted on a rolling quarterly basis thereafter. For further inquiries, contact Sharria T. Wells at sharria.t.wells.civ@health.mil.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Miniaturized Large Volume Infusion System
    Buyer not available
    The Department of Defense, through the Army Medical Research Acquisition Activity, is seeking information from vendors regarding a Miniaturized Large Volume Infusion System as part of a Request for Information (RFI) numbered HT9425-25-RFI-MMCIP. The system must meet specific requirements, including the capability to deliver multiple fluids and medications simultaneously, compact size and weight restrictions, and compliance with FDA approvals, while also being suitable for both military and civilian applications. This initiative is crucial for enhancing patient care in military settings, particularly in austere environments, and aims to refine procurement requirements based on industry feedback. Interested vendors should submit their detailed responses by March 28, 2025, and can contact Katherine Ramsburg at katherine.j.ramsburg.civ@health.mil or 301-619-2651 for further information.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Remote Health Readiness Program 4 (RHRP-4)
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting proposals for the Remote Health Readiness Program 4 (RHRP-4), which aims to provide comprehensive medical and dental readiness services to military personnel, including both active duty and reserve components. The contract, valued at up to $1.61 billion, will be structured as an Indefinite Delivery Indefinite Quantity (IDIQ) contract over a ten-year period, encompassing a transition phase followed by a base period and nine optional years of performance. This initiative is crucial for maintaining the health and operational readiness of service members, ensuring they receive necessary assessments and treatments across various modalities, including in-clinic and virtual care. Interested contractors should contact Nakaura C. Yusuf at nakaura.c.yusuf.civ@health.mil or call 703-681-5821 for further details regarding the solicitation process.